This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Raymond, P D Articles by Marsh, N A Search for Related Content PubMed PubMed Citation Articles by Raymond, P D Articles by Marsh, N A Social Bookmarking                   What's this?

Heparin monitoring during cardiac surgery. Part 1: validation of whole-blood heparin concentration and activated clotting time

Research Concentration in Biological and Medical Sciences, School of Life Sciences, Queensland University of Technology, Brisbane, Australia, Perfusion Services, The Prince Charles Hospital, Brisbane, Australia, p.raymond{at}tpg.com.au

M J Ray

Department of Haematology, The Prince Charles Hospital, Brisbane, Australia

S N Callen

Department of Haematology, The Prince Charles Hospital, Brisbane, Australia

N A Marsh

Research Concentration in Biological and Medical Sciences, School of Life Sciences, Queensland University of Technology, Brisbane, Australia

There is limited published data on the agreement between techniques for monitoring heparin levels. The aim of this study was to validate the Hepcon/HMS, with particular focus on the agreement with laboratory anti-Xa assay. The performances of two ACT instruments - Hemochron and HemoTec - were also evaluated, including an assessment for interchangeability. Blood samples from 42 adult cardiopulmonary bypass (CPB) patients were analysed for activated clotting time (ACT), whole-blood heparin concentration (Hepcon/HMS) and anti-factor Xa (anti-Xa) plasma heparin concentration. Agreement between measures was determined using the method of Bland and Altman. Simple analysis of agreement between the Hepcon and anti-Xa heparin revealed the Hepcon has a mean bias of -0.46 U/mL, with the limits of agreement ±1.12 U/mL. The comparison between ACT instruments indicated a mean difference of -96 seconds for the HemoTec, with limits of ±265 seconds. The Hepcon/HMS instrument displayed satisfactory agreement with anti-Xa plasma heparin concentration, as the expected variation would not be expected to cause problems in the clinical setting. Agreement between the two measurements of ACT may be satisfactory, provided each is assigned a different target value.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. Dunning, M. Versteegh, A. Fabbri, A. Pavie, P. Kolh, U. Lockowandt, S. A.M. Nashef, and on behalf of the EACTS Audit and Guidelines Commit Guideline on antiplatelet and anticoagulation management in cardiac surgery. Eur. J. Cardiothorac. Surg., July 1, 2008; 34(1): 73 - 92. [Abstract] [Full Text] [PDF]

				N. M. Milovic, J. R. Behr, M. Godin, C.-S. J. Hou, K. R. Payer, A. Chandrasekaran, P. R. Russo, R. Sasisekharan, and S. R. Manalis Monitoring of heparin and its low-molecular-weight analogs by silicon field effect PNAS, September 5, 2006; 103(36): 13374 - 13379. [Abstract] [Full Text] [PDF]

				K. A. A. Aziz, O. Masood, J. A. Hoschtitzky, and A. Ronald Does use of the Hepcon(R) point-of-care coagulation monitor to optimise heparin and protamine dosage for cardiopulmonary bypass decrease bleeding and blood and blood product requirements in adult patients undergoing cardiac surgery? Interactive CardioVascular and Thoracic Surgery, August 1, 2006; 5(4): 469 - 482. [Abstract] [Full Text] [PDF]